HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice.

Abstract
A prominent feature of sickle cell anemia is the presence of dehydrated red blood cells (RBCs) in circulation. Loss of potassium (K(+)), chloride (Cl(-)), and water from RBCs is thought to contribute to the production of these dehydrated cells. One main route of K(+) loss in the RBC is the Gardos channel, a calcium (Ca(2+))-activated K(+) channel. Clotrimazole (CLT), an inhibitor of the Gardos channel, has been shown to reduce RBC dehydration in vitro and in vivo. We have developed a chemically novel compound, ICA-17043, that has greater potency and selectivity than CLT in inhibiting the Gardos channel. ICA-17043 blocked Ca(2+)-induced rubidium flux from human RBCs with an IC(50) value of 11 +/- 2 nM (CLT IC(50) = 100 +/- 12 nM) and inhibited RBC dehydration with an IC(50) of 30 +/- 20 nM. In a transgenic mouse model of sickle cell disease (SAD), treatment with ICA-17043 (10 mg/kg orally, twice a day) for 21 days showed a marked and constant inhibition of the Gardos channel activity (with an average inhibition of 90% +/- 27%, P <.005), an increase in RBC K(+) content (from 392 +/- 19.9 to 479.2 +/- 40 mmol/kg hemoglobin [Hb], P <.005), a significant increase in hematocrit (Hct) (from 0.435 +/- 0.007 to 0.509 +/- 0.022 [43.5% +/- 0.7% to 50.9% +/- 2.2%], P <.005), a decrease in mean corpuscular hemoglobin concentration (MCHC) (from 340 +/- 9.0 to 300 +/- 15 g/L [34.0 +/- 0.9 to 30 +/- 1.5 g/dL], P <.05), and a left-shift in RBC density curves. These data indicate that ICA-17043 is a potent inhibitor of the Gardos channel and ameliorates RBC dehydration in the SAD mouse.
AuthorsJonathan W Stocker, Lucia De Franceschi, Grant A McNaughton-Smith, Roberto Corrocher, Yves Beuzard, Carlo Brugnara
JournalBlood (Blood) Vol. 101 Issue 6 Pg. 2412-8 (Mar 15 2003) ISSN: 0006-4971 [Print] United States
PMID12433690 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Acetamides
  • Calcium Channel Blockers
  • Potassium Channels, Calcium-Activated
  • Trityl Compounds
  • Clotrimazole
  • Rubidium
  • Calcium
  • senicapoc
Topics
  • Acetamides (chemistry, pharmacology, therapeutic use)
  • Anemia, Sickle Cell (blood, drug therapy)
  • Animals
  • Calcium (pharmacology)
  • Calcium Channel Blockers (pharmacology)
  • Clotrimazole (chemistry, pharmacology, therapeutic use)
  • Erythrocytes (chemistry, drug effects, physiology)
  • Female
  • Humans
  • Hypoxia
  • Male
  • Mice
  • Mice, Transgenic
  • Potassium Channels, Calcium-Activated (antagonists & inhibitors, metabolism)
  • Rubidium (blood)
  • Trityl Compounds (chemistry, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: